drugset / Trial / NCT05662306

C-Cog in Early Course Schizophrenia Study

NCT05662306

Phase 4 Terminated 1 enrolled University of Miami Alkermes, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the role of clinical stability in functional recovery. in first episode schizophrenia.

Timeline

Start
2024-01-23
Primary completion
2025-03-03
Completion
2025-03-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Lauroxil Small molecule 1064 mg Intramuscular

Indications